These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 19704173)

  • 41. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis.
    Boivin G; Goyette N; Farhan M; Ives J; Elston R
    J Clin Virol; 2012 Mar; 53(3):208-13. PubMed ID: 22237003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.
    Iwasenko JM; Scott GM; Naing Z; Glanville AR; Rawlinson WD
    Transpl Infect Dis; 2011 Apr; 13(2):145-53. PubMed ID: 21070537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Successful ganciclovir treatment of primary cytomegalovirus infection containing the UL97 mutation N510S in an intestinal graft recipient.
    Bachmann R; Hamprecht K; Lange J; Ladurner R; Nadalin S; Jahn G; Königsrainer A; Heininger A
    Infection; 2013 Aug; 41(4):875-9. PubMed ID: 23546999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
    Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S
    Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human cytomegalovirus (CMV) UL97 D605E mutation has a higher prevalence in infants with primary CMV infection compared with transplant recipients with CMV recurrence.
    Sun J; Cao G; Zhang L; Zhang Y; Zhao Z; Hu J; Ji Y
    Transplant Proc; 2012 Dec; 44(10):3022-5. PubMed ID: 23195018
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Disease by CMV resistant to Ganciclovir. Should plasma valganciclovir levels be monitored in high risk patients?].
    Sola E; Vega E; Gutiérrez C; López V; Cabello M; Burgos D; González Molina M; Siles J
    Nefrologia; 2009; 29(2):180-1. PubMed ID: 19396331
    [No Abstract]   [Full Text] [Related]  

  • 47. [Strains of ganciclovir-resistant cytomegalovirus].
    Calicó I; García E; Cortés A; Gavaldá J; Roman A; Valle I
    Enferm Infecc Microbiol Clin; 1999; 17(7):330-4. PubMed ID: 10535184
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.
    Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S
    Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.
    Fischer L; Laib Sampaio K; Jahn G; Hamprecht K; Göhring K
    Antiviral Res; 2013 Dec; 100(3):575-7. PubMed ID: 24120366
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
    Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
    Limaye AP; Corey L; Koelle DM; Davis CL; Boeckh M
    Lancet; 2000 Aug; 356(9230):645-9. PubMed ID: 10968438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies.
    Majeed A; Latif A; Kapoor V; Sohail A; Florita C; Georgescu A; Zangeneh T
    Transplant Proc; 2018 Dec; 50(10):3756-3762. PubMed ID: 30586840
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.
    Timpone JG; Yimen M; Cox S; Teran R; Ajluni S; Goldstein D; Fishbein T; Kumar PN; Matsumoto C
    Transpl Infect Dis; 2016 Apr; 18(2):202-9. PubMed ID: 26853894
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection.
    Cunha-Bang Cd; Kirkby N; Sønderholm M; Sørensen SS; Sengeløv H; Iversen M; Rasmussen A; Gustafsson F; Frederiksen CM; Kjaer J; Lepri AC; Lundgren JD
    Am J Transplant; 2013 Feb; 13(2):458-66. PubMed ID: 23282281
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of resistance-associated mutations in UL54 and UL97 genes of circulating cytomegalovirus strains isolated in a medical center in Taiwan.
    Shao PL; Lu MY; Liau YJ; Kao CL; Chang SY; Huang LM
    J Formos Med Assoc; 2012 Aug; 111(8):456-60. PubMed ID: 22939665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial.
    Åsberg A; Humar A; Rollag H; Jardine AG; Kumar D; Aukrust P; Ueland T; Bignamini AA; Hartmann A
    Clin Infect Dis; 2016 May; 62(9):1154-60. PubMed ID: 26908810
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.
    West P; Schmiedeskamp M; Neeley H; Oberholzer J; Benedetti E; Kaplan B
    Transpl Infect Dis; 2008 Apr; 10(2):129-32. PubMed ID: 17605740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D.
    Iwasenko JM; Scott GM; Rawlinson WD; Keogh A; Mitchell D; Chou S
    J Med Virol; 2009 Mar; 81(3):507-10. PubMed ID: 19152402
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mass spectrometry-based comparative sequencing to detect ganciclovir resistance in the UL97 gene of human cytomegalovirus.
    Posthuma CC; van der Beek MT; van der Blij-de Brouwer CS; van der Heiden PL; Marijt EW; Spaan WJ; Claas EC; Nederstigt C; Vossen AC; Snijder EJ; Kroes AC
    J Clin Virol; 2011 May; 51(1):25-30. PubMed ID: 21388868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.
    Campos AB; Ribeiro J; Boutolleau D; Sousa H
    Rev Med Virol; 2016 May; 26(3):161-82. PubMed ID: 26990717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.